iOmx Therapeutics
Germany - MartinsriedBiotechnology
Focus: iOmx Therapeutics is a Germany-based cancer immunotherapy biotech focused on early-stage oncology programs. The company is pre-revenue with a lean pipeline currently in Phase 1/2 development.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Open Jobs
1
Should You Work at iOmx Therapeutics?
AI assessmentiOmx offers early-stage upside for immunotherapy specialists willing to tolerate pre-clinical risk, but limited hiring and pipeline maturity make this a speculative, not stable, career move.
Why Work Here
- Early-stage immunotherapy focus aligns with high-growth oncology segment and emerging science in cancer treatment
- Recent $125M funding rescue (Galapagos assets acquisition, April 2026) signals fresh capital and strategic repositioning
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OMX-0407
Solid TumorClinical Trials (1)
NCT05826600A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
Phase 1/2Help build intelligence for iOmx Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.